Skip to main content

CollPlant

MaterialsRehovot, IsraelFounded 2004· One of 1000 Materials companies tracked by AMPulse

A regenerative and aesthetic medicine company developing innovative 3D bioprinting technologies and products based on proprietary plant-derived recombinant human collagen (rhCollagen) for tissue regeneration, organ manufacturing, and medical aesthetics.

CEO / Founder
Yehiel Tal
Team Size
51-200
Stage
Public
Total Funding
$30.6M
Latest Round
Post-IPO
Key Investors
Pontifax, Docor International, Alpha Capital Partners, Ami Sagy

Technology & Products

Key Products

Collink.3D® BioInks - First and only human collagen-based bioink line for 3D bioprinting, BioFlex - Ready-to-print rhCollagen-based kit for Digital Light Processing (DLP) bioprinting applications (launched Feb 2026), Regenerative Breast Implants - 3D bioprinted commercial-sized (200cc) implants, Photocurable Dermal Fillers - Light-activated rhCollagen aesthetic treatments, rhCollagen Raw Material - Pure recombinant human collagen for biomedical applications, Tissue/Organ-on-a-Chip Systems - Alternative to animal testing models, Vergenix™ STR - Tendon-repair product combining rhCollagen with platelet-rich plasma (PRP)

Technical position · AMPulse analysis

Proprietary plant-based recombinant human Type I collagen production technology that provides mass-production scalability, batch-to-batch consistency, high purity, zero risk of human pathogen transmission, elimination of immune response compared to animal-derived collagen, and full biocompatibility with human tissue - enabling revolutionary applications in 3D bioprinting and regenerative medicine that were previously impossible.

Patent position

CollPlant filed 5 patent families in 2022 to 2024, down 29% from 7 in 2019 to 2021, while tracked AM filings in the same patent offices fell 20%. Across all years it holds 18 families, against CELLINK's 52. AMPulse analysis

Filing momentum
5 families filed 2022–2024, 7 in 2019–2021 (-29%); all tracked AM filings in the same offices -20%
Focus, 2019–2021 → 2022–2024
Applications 100% → 100%
Filed in
US 39%WO 28%EP 22%CN 11%
Named competitors, AM patent families
CELLINK 523D Systems 300Allevi 5Advanced BioMatrix 3

18 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Only commercially viable technology for mass production of plant-derived recombinant human Type I collagen (rhCollagen) that is identical to human body-produced collagen, eliminating immune response risks while providing scalable, high-purity, and consistent collagen for 3D bioprinting of tissues/organs and regenerative medicine applications.

How They Differentiate

Only company producing recombinant human Type I collagen (rhCollagen) from genetically engineered tobacco plants - identical to human body collagen with zero immune response risk, full biocompatibility, and scalable mass production unlike animal-derived collagen competitors

Market & Competition

Target Customers

Medical device manufacturers, pharmaceutical companies, research institutions, aesthetic medicine practitioners, tissue engineering companies, and organizations seeking alternatives to animal testing in drug development and safety studies

Industry Verticals

Regenerative Medicine, 3D Bioprinting, Medical Aesthetics, Tissue Engineering, Medical Devices, Pharmaceutical Research, Orthopedics, Advanced Wound Care

Competitors

CELLINK (BICO Group); 3D Systems (Allevi); Advanced BioMatrix

Growth & Milestones

Growth Metrics

Public company (NASDAQ: CLGN) since 2018; early revenue stage with $515K revenue in 2024 and $2M AbbVie milestone payment in Feb 2025; expanding North American commercial operations

Major Milestones

NASDAQ listing commenced January 31, 2018, Strategic partnership with AbbVie for medical aesthetics (ongoing with $2M milestone payment Feb 2025), Collaboration with Stratasys for regenerative breast implants using P3 technology, License agreement with United Therapeutics for 3D bioprinted lungs (Oct 2018), Mayo Clinic validation of fully humanized 3D bioprinted skin model (Oct 2025), Launch of BioFlex DLP bioprinting kit (Feb 2026)

Notable Customers

AbbVie (Allergan Aesthetics); United Therapeutics; Stratasys; Mayo Clinic; STEMCELL Technologies

https://collplant.com

Recent coverage of CollPlant

AM patents

AM-relevant patents linked to this company.

Patents
20
Granted
4
Families
18

Leading domains: application (20), process (20), material (9)

Filings by year: 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 1

  1. DERMAL FILLERS AND APPLICATIONS THEREOF2019211854 · WO
  2. COLLAGEN-CONTAINING CURABLE FORMULATIONS04422707 · EP
  3. ADDITIVE MANUFACTURING USING RECOMBINANT COLLAGEN-CONTAINING FORMULATION2018225076 · WO
  4. FORMULATIONS FOR USE IN ADDITIVE MANUFACTURING, CONTAINING A TETRACYCLINE COMPOUND AS A LIGHT-ABSORBING SUBSTANCE2024089699 · WO
  5. COLLAGEN-CONTAINING CURABLE FORMULATIONS20250295791 · US

Funding rounds

  • Strategic Investment$2.6M2026-06Lead: H.C. Wainwright & Co. (placement agent) · Source: PR Newswire / CollPlant IR, closed ~July 1-6 2026
  • Registered Direct Offering$2.0M2026-02Lead: N/A · Source: PR Newswire
  • Registered Direct Offering$3.6M2025-05Lead: N/A · Source: Company Press Release
  • Post-IPO$4.45M2020-02Lead: N/A · Source: Crunchbase
  • Convertible Loans$5.5M2019-09Lead: N/A · Source: Company Press Release

Why this company matters

AMPulse analysis, not a company disclosure

CollPlant occupies a unique position at the intersection of regenerative medicine and 3D bioprinting as the only company capable of mass-producing recombinant human Type I collagen (rhCollagen) from genetically engineered tobacco plants. This plant-derived collagen is structurally identical to human collagen, eliminating the immune response risks and batch variability associated with animal-derived collagen, while enabling scalable production for tissue engineering and organ manufacturing.

The company's core technology platform centers on proprietary genetic engineering of tobacco plants to express human collagen, which is then purified and formulated into bioinks. Its Collink.3D BioInks are the first and only human collagen-based bioink line for extrusion-based bioprinting. In February 2026, CollPlant launched BioFlex, a ready-to-print rhCollagen kit for Digital Light Processing (DLP) bioprinting. The company also develops photocurable dermal fillers for medical aesthetics and has produced 3D bioprinted commercial-sized regenerative breast implants using Stratasys' P3 technology.

CollPlant serves medical device manufacturers, pharmaceutical companies, and research institutions. Notable partners include AbbVie (Allergan Aesthetics) for aesthetic product development, Stratasys for industrial-scale bioprinting of breast implants, United Therapeutics for 3D bioprinted lungs, and the Mayo Clinic, which validated the first fully humanized 3D bioprinted skin model for non-animal testing. The company also supplies rhCollagen raw material and tissue-on-a-chip systems as alternatives to animal testing.

CollPlant went public on NASDAQ in 2018 and reported $515,000 in revenue for 2024, supplemented by a $2 million milestone payment from AbbVie in February 2025. Its primary competitive differentiator is the plant-based rhCollagen production method, which offers mass-production scalability and zero pathogen transmission risk, setting it apart from animal-derived collagen suppliers such as CELLINK (BICO Group) and Advanced BioMatrix. Key open questions include the pace of commercial adoption for its bioinks and the timeline to revenue from its regenerative breast implant and dermal filler programs.